Coronavirus Notebook: UK Adds Paxlovid To PANORAMIC Study, Germany Funds Adrecizumab Phase II Trial
Executive Summary
RedHill’s opaganib has shown “potent inhibition” of the Omicron variant in early studies, while the EMA has found no links between the mRNA vaccines and autoimmune hepatitis.